Literature DB >> 24229481

Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: a randomized controlled trial.

S Salzer1, C Cropp2, U Jaeger2, O Masuhr2, A Streeck-Fischer2.   

Abstract

BACKGROUND: Co-morbid disorders of conduct and emotions can be regarded as childhood antecedents of further negative developments (e.g. manifestation of personality disorders in adulthood). We evaluated a manualized psychodynamic therapy (PDT) for adolescents with these co-morbid disorders.
METHOD: In a randomized controlled trial (RCT), 66 adolescents diagnosed with mixed disorders of conduct and emotions (F92 in ICD-10) were randomly assigned to a manualized in-patient PDT group or a waiting list/treatment-as-usual (WL/TAU) control condition. Diagnoses according to DSM-IV were also documented. Patients were compared using rates of remission as the primary outcome. The Global Severity Index (GSI) and the Strengths and Difficulties Questionnaire (SDQ) were used as secondary measures. Assessments were performed at baseline, post-treatment and at the 6-month follow-up.
RESULTS: The sample consisted of severely impaired adolescents with high rates of further co-morbid disorders and academic failure. Patients in the treatment group had a significantly higher rate of remission [odds ratio (OR) 26.41, 95% confidence interval (CI) 6.42-108.55, p < 0.001]. Compared with the control group, the PDT group resulted in significantly better outcomes on the SDQ (p = 0.04) but not the GSI (p = 0.18), with small between-group effect sizes (SDQ: d = 0.38, GSI: d = 0.18). However, the scores of patients treated with PDT were post-treatment no longer significantly different from normative data on the GSI and within the normal range on the SDQ. The effects in the treatment group were stable at follow-up. Furthermore, most patients were reintegrated into educational processes.
CONCLUSION: PDT led to remarkable improvement and furthered necessary preconditions for long-term stabilization. In future, PDT should be compared to other strong active treatments.

Entities:  

Mesh:

Year:  2013        PMID: 24229481     DOI: 10.1017/S003329171300278X

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  5 in total

1.  Systematic Review and Meta-Analyses of Psychotherapies for Adolescents With Subclinical and Borderline Personality Disorder: Methodological Issues.

Authors:  Mie Sedoc Jørgensen; Ole Jakob Storebø; Erik Simonsen
Journal:  Can J Psychiatry       Date:  2019-12-09       Impact factor: 4.356

2.  Systematic Review and Meta-Analyses of Psychotherapies for Adolescents with Subclinical and Borderline Personality Disorder: A Reply to the Commentary by Jørgensen, Storebø, and Simonsen.

Authors:  Jennifer Wong; Anees Bahji; Sarosh Khalid-Khan
Journal:  Can J Psychiatry       Date:  2020-01-03       Impact factor: 4.356

3.  Psychological therapies for people with borderline personality disorder.

Authors:  Ole Jakob Storebø; Jutta M Stoffers-Winterling; Birgit A Völlm; Mickey T Kongerslev; Jessica T Mattivi; Mie S Jørgensen; Erlend Faltinsen; Adnan Todorovac; Christian P Sales; Henriette E Callesen; Klaus Lieb; Erik Simonsen
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04

4.  Psychological therapies for adolescents with borderline personality disorder (BPD) or BPD features-A systematic review of randomized clinical trials with meta-analysis and Trial Sequential Analysis.

Authors:  Mie Sedoc Jørgensen; Ole Jakob Storebø; Jutta M Stoffers-Winterling; Erlend Faltinsen; Adnan Todorovac; Erik Simonsen
Journal:  PLoS One       Date:  2021-01-14       Impact factor: 3.240

5.  Improving adolescent mental health and resilience through a resilience-based intervention in schools: study protocol for a randomised controlled trial.

Authors:  Julia Dray; Jenny Bowman; Megan Freund; Elizabeth Campbell; Luke Wolfenden; Rebecca K Hodder; John Wiggers
Journal:  Trials       Date:  2014-07-18       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.